

## DIAGNOSTIC ACCURACY OF IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF HELICOBACTER PYLORI INFECTION IN GASTRIC BIOPSIES RECEIVED IN SIR GANGARAM HOSPITAL LAHORE

Dr Ammara Saeed<sup>1</sup>, Dr Asima Naz<sup>2</sup>, Dr Saba Ahmad<sup>3</sup>, Dr Hira Mubeen<sup>4</sup>,  
Dr Pakiza Liaqat<sup>5</sup>, Ayeeza Asghar<sup>6</sup>

<sup>1,2,3,4,5</sup> Sir Gangaram Hospital Lahore  
<sup>6</sup>CMH Lahore

### ABSTRACT

**Background:** The stomach epithelium is colonised by gram-negative spiral-shaped *Helicobacter pylori*. Chronic gastritis, ulcers, adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma are linked to Pylori infection. Basic H&E stain can detect it. The particular method of immunohistochemistry is reliable for *H. pylori* diagnosis. Previous research had mixed outcomes. This research was done to gather local demographic data.

**Objective:** To ascertain the diagnostic precision of immunohistochemistry in identifying *Helicobacter pylori* infection in stomach samples obtained in the histopathology department using H&E as the gold standard.

**Study Design:** Cross Sectional Study

**Study place and duration:** Department of Pathology, Sir Ganga Ram Hospital, Lahore from 21-6-2024 to 21-12-2024.

**Patients and methodology:** 260 samples were received from gastroenterology department and were divided in two parts. On one part, immunohistochemistry was applied and findings were recorded. On second part, H&E was applied and findings were recorded. All the data was recorded in proforma while later on analyzed in SPSS 20.0.

**Results:** Patients in this research ranged in age from 16 to 75 years, with a mean age of  $41.73 \pm 16.64$  years. The male-to-female ratio was 1:2.25, with 80 (30.8%) male and 180 (69.2%) female patients. The immunohistochemical test for *H. pylori* infection has 85.2% sensitivity, 100% specificity, 100% PPV, 93.7% NPV, and 95.4% diagnostic accuracy.

**Conclusion:** Thus, immunohistochemistry is found to be reliable enough to detect *H. pylori* infection in gastric biopsies.

**Keywords:** immunohistochemistry, helicobacter Pylori infection, gastric biopsies, histopathology, hematoxylin and eosin

### INTRODUCTION

*Helicobacter pylori* is a gram negative spiral shaped bacterium which colonizes the gastric epithelium.<sup>1</sup> A mucus layer shields motile, microaerophilic bacteria from the acidic gastrointestinal environment.<sup>2, 3</sup> It affects about more than 50% of the population of the world.<sup>4</sup> Immunohistochemistry detected 37.1% of *Helicobacter pylori* whereas histology detected 32.4%.<sup>5</sup> Contagious food, water, and poverty spread it. In poorer nations like Pakistan, the infectivity is still high owing to low socioeconomic position, while in wealthy countries, improved standards of living have reduced it.<sup>5</sup> Adenocarcinoma, gastric mucosa-associated lymphoid tissue lymphoma, chronic gastritis, and ulcers are linked to pylori infection. Gut inflammation, including ulcerative colitis and autoimmune illnesses, involves it. Aliancillary studies and immunohistochemistry may increase specificity by 90-100% over normal H&E stain.<sup>6</sup> According to the four

# The Research of Medical Science Review

authors, blindly evaluating hematoxylin and eosin slides found H pylori with 100%, 95%, and 100% sensitivity/specificity.<sup>7</sup>

Immunohistochemistry is a special technique that uses specific binding ability between an antibody and antigen to detect Pylori bacteria in gastric biopsies. The main steps after fixation of the specimen is deparaffination, antigen retrieval, blocking, primary and secondary antibody incubation and staining.<sup>8</sup> After immunohistochemistry, dark brown thread like bacteria can be identified on light microscope. Staining pattern of Pylori can be diffuse, dot like granular or spiral.<sup>9</sup>

In this research, immunohistochemistry is tested for its ability to detect helicobacter Pylori in stomach samples from histology. Research shows that immunohistochemistry can diagnose H. pylori. However, prior investigations found different findings. Thus, we aim to undertake this research to see whether immunohistochemistry is trustworthy for local populations. It will boost our knowledge and practice.

## OBJECTIVE

To ascertain the diagnostic precision of immunohistochemistry in identifying Helicobacter pylori infection in stomach samples obtained in the histopathology department using H&E as the gold standard.

## MATERIALS AND METHODS

**Study Design:** Cross Sectional Study

**Study place and duration:** Department of Pathology, Sir Ganga Ram Hospital, Lahore from 21-6-2024 to 21-12-2024.

**Sample Size:** By using sensitivity & specificity calculator, sample size of 260 cases is calculated with 95% confidence level, prevalence of H. pylori i.e. 37.1%,<sup>5</sup> sensitivity of immunohistochemistry i.e. 87.5% with 8.5% margin of error and specificity of immunohistochemistry i.e. 94.44% with 3.5% margin of error.<sup>10</sup>

**Sample technique:** Non-probability, consecutive sampling

### Sample Selection:

**Inclusion Criteria:** Gastric biopsies of patients of age 16-75 years, both; male and female patients, received for histopathological examination were included in the study.

**Exclusion Criteria:** Autolyzed specimen or tissue with processing defects, inappropriately stored samples or patients taking proton pump inhibitors were excluded from the study.

**Data Collection Procedure:** The ethical review board approved 260 gastroenterology samples. Data collected included name, age, gender, BMI, symptom duration, residence, food, water consumption, smoking (>5 pack years), diabetes (BSR> 200 mg/dl), and hypertension (BP≥140/90 mmHg). Samples were split. Part of the study used immunohistochemistry and documented results. Results from immunohistochemistry were positive or negative. EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse kit (Dako) identified and visualised bound antibodies, indicating positive immunohistochemistry. The second section used hematoxylin and eosin and reported results. HE staining verified positive or negative findings. Positive urease test, spiral-shaped H. pylori, and modified Giemsa staining indicated a positive H&E staining. Proforma records all data.

**Statistical Analysis:** It was performed using SPSS system for windows SPSS 20.0. Normality was checked by Shapiro-Wilk test. Mean and standard deviation was calculated for quantitative variables, e.g. age, BMI, duration of symptoms. Qualitative variables gender, residence, diet pattern, water use, smoking, diabetes, hypertension, and H. pylori (detected on immunohistochemistry and H&E stain) were expressed as

# The Research of Medical Science Review

frequency and percentage. 2x2 table was generated to calculate sensitivity, specificity, PPV, NPV and diagnostic accuracy of immunohistochemistry taking H&E stain as gold standard.

## RESULTS:

In this study, the mean age of patients was  $41.73 \pm 16.64$  years with age range from 16 to 75 years. There were 80 (30.8%) male patients while 180 (69.2%) female patients with male-to-female ratio of 1:2.25. The mean BMI was noted as  $22.88 \pm 1.77$  kg/m<sup>2</sup>. The mean duration of symptoms was  $5.17 \pm 2.76$  months. Out of 260 patients, 109 (41.9%) were living in rural areas, 51 (19.6%) were living in urban areas, 93 (35.8%) were residing in semi-urban areas while 7 (2.7%) were residing in urban slums. Out of 260 patients, 161 (61.9%) were taking home made food, while 69 (26.5%) were taking mostly street food (about >3 times per week), 24 (9.2%) were consuming fast food (>3 times per week), while 6 (2.3%) had mess. It was also noted that about 189 (72.7%) patients were using plain tap water, and 71 (27.3%) were using filtered water while no one (0%) using boiled water in routine. Out of 260, 37 (14.2%) were smokers, 88 (33.8%) were diabetic and 128 (49.2%) had history of hypertension. Table I


On immunohistochemistry, there were 69 (26.5%) positive while 191 (73.5%) negative cases. On H&E staining, there were 81 (31.2%) positive while 179 (68.8%) negative cases. Fig I

2x2 contingency table was generated and diagnostic accuracy of immunohistochemistry was calculated. The immunohistochemistry showed sensitivity of 85.2%, Specificity of 100%, PPV of 100%, NPV of 93.7% and overall diagnostic accuracy of 95.4% for diagnosis of H. pylori infection. Table II

**Table I: Baselines characteristics of patients enrolled in the study (n = 260)**

	F (%), Mean $\pm$ SD
Age (in years)	41.73 $\pm$ 16.64 (16-75)
Gender	
Male	80 (30.8%)
Female	180 (69.2%)
BMI (in kg/m <sup>2</sup> )	22.88 $\pm$ 1.77
Duration of symptoms (in months)	5.17 $\pm$ 2.76
Residence	
Rural	109 (41.9%)
Urban	51 (19.6%)
Semi-urban	93 (35.8%)
Urban slums	7 (2.7%)
Diet pattern	
Home-made	161 (61.9%)
Street food	69 (26.5%)
Fast food	24 (9.2%)
Mess	6 (2.3%)
Water usage	
Tap water	189 (72.7%)
Filtered	71 (27.3%)
Boiled	0 (0%)
History	
Smoking	37 (14.2%)
Diabetes mellitus	88 (33.8%)
Hypertension	128 (49.2%)

# The Research of Medical Science Review



**Fig 1: Distribution of positive and negative findings on immunohistochemistry and H&E staining**

**Table II: 2x2 table showing accuracy of immunohistochemistry for diagnosis H pylori against H&E staining**

		H&E staining		Total
		Positive	Negative	
Immunohistochemistry	Positive	69	0	69
	Negative	12	179	191
Total		81	179	260

Sensitivity: 85.2%, Specificity: 100%, PPV: 100%, NPV: 93.7% and diagnostic accuracy: 95.4%.

## DISCUSSION:

Accurate *H. pylori* diagnosis is essential for managing several gastroduodenal disorders.<sup>11</sup> Each invasive and non-invasive *H. pylori* diagnostic test has its pros and cons in various clinical settings. In clinical practice, there is no gold standard, although different methods provide more trustworthy outcomes.<sup>12-14</sup>

*H. pylori* infection is initially detected by histology, the gold standard. Staining is important in histology, and routine H&E staining, Giemsa, Warthin-Starry, Hp silver stain, toluidine blue, acridine orange, McMullen, Genta, Dieterle, and immunohistochemical stain may identify *H. pylori*.<sup>15, 16</sup> In clinical practice, H&E stain is frequently adequate to diagnose *H. pylori* infection, even though immunohistochemical stain is most sensitive and specific. For biopsy specimens with moderate or severe chronic gastritis but no *H. pylori* in H&E staining, ancillary stain is advised. If using auxiliary stain to identify *H. pylori*, immunohistochemical stain is best.<sup>15, 17</sup>

In our research, immunohistochemistry had 85.2% sensitivity, 100% specificity, 100% PPV, 93.7% NPV, and 95.4% diagnostic accuracy for *H. pylori* infection. Immunohistochemical staining is sensitive, specific, rapid, and has the lowest interobserver variance for *H. pylori*.<sup>18</sup>

A comparable research by Jahanzeb and Nagi reported that Immunofluorescent has 90% sensitivity and 100% specificity for *H. pylori* detection.<sup>19</sup> Our investigation almost matched these results. Another research by Akeel et al. found that immunohistochemical staining has 87.50% sensitivity and 94.44% specificity for *H. pylori* infection identification.<sup>10</sup>

A retrospective study of 200 gastric biopsy specimens by Smith et al. found that H&E can detect *H. pylori* in 91% of cases and 100% of cases, making it the fastest and cheapest test for gastric biopsies.<sup>20</sup>

Immunohistochemical staining had better sensitivity (87.5%) and specificity (94.44%) than H&E and modified Giemsa staining, concurring with earlier investigations.<sup>21, 22</sup> Immunohistochemical staining cannot assess histopathological changes like H&E. Direct histopathological staining for *H. pylori* identification is

# The Research of Medical Science Review

most reliable with immunohistochemical staining. Immunohistochemical staining is sensitive and selective because it uses particular antibodies, can identify unusual bacterial forms such as coccoid forms, and has low false-positive rates. When standard regular procedures fail to identify *H. pylori* in chronic gastritis caused by limited infection or unusual bacterium distribution in afflicted tissue, immunohistochemistry is indicated. High cost limits immunohistochemical staining for regular diagnostics. Therefore, immunohistochemistry labelling is advised for mild *H. pylori* infection.<sup>10, 23</sup>

## CONCLUSION:

Thus, immunohistochemistry is found to be reliable enough to detect *H. pylori* infection in gastric biopsies. Now in future, instead of going for H&E staining, we will use immunohistochemistry to detect *H. pylori* infection in gastric biopsies.

**CONFLICT OF INTEREST:** None

## ACKNOWLEDGEMENT:

## REFERENCES:

1. Trindade LMDF, de Oliveira Menezes LB, de Souza Neta AM, Rolemberg PCL, Souza LD, de Carvalho Barreto ID, et al. Prevalence of *Helicobacter pylori* infection in samples of gastric biopsies. *Gastroenterology research*. 2017;10(1):33.
2. Alipour M. Molecular mechanism of *Helicobacter pylori*-induced gastric cancer. *Journal of gastrointestinal cancer*. 2021;52:23-30.
3. Kim J, Wang TC. *Helicobacter pylori* and gastric cancer. *Gastrointestinal Endoscopy Clinics*. 2021;31(3):451-65.
4. Hirukawa S, Sagara H, Kaneto S, Kondo T, Kiga K, Sanada T, et al. Characterization of morphological conversion of *Helicobacter pylori* under anaerobic conditions. *Microbiology and immunology*. 2018;62(4):221-8.
5. Ngaiza AI, Yahaya JJ, Mwakimonga AK, Vuhahula E, Mnango L, Mwakigonja AR, et al. Histologic detection of *Helicobacter pylori* by the immunohistochemical method using anti-*Helicobacter pylori* polyclonal antibody: A cross-sectional study of patients with gastric pathologies at the Muhimbili National Hospital in Dar-es-salaam, Tanzania. *Arab Journal of Gastroenterology*. 2022;23(1):7-14.
6. Farouk WI, Hassan NH, Ismail TR, Daud IS, Mohammed F. Warthin-Starry staining for the detection of *Helicobacter pylori* in gastric biopsies. *The Malaysian Journal of Medical Sciences: MJMS*. 2018;25(4):92.
7. Wang XI, Zhang S, Abreo F, Thomas J. The role of routine immunohistochemistry for *Helicobacter pylori* in gastric biopsy. *Annals of Diagnostic Pathology*. 2010;14(4):256-9.
8. Magaki S, Hojat SA, Wei B, So A, Yong WH. An Introduction to the Performance of Immunohistochemistry. In: Yong WH, editor. *Biobanking: Methods and Protocols*. New York, NY: Springer New York; 2019. p. 289-98.
9. Liscia DS, D'Andrea M, Biletta E, Bellis D, Demo K, Ferrero F, et al. Use of digital pathology and artificial intelligence for the diagnosis of *Helicobacter pylori* in gastric biopsies. *Pathologica*. 2022;114(4):295.
10. Akeel M, Elhafey A, Shehata A, Elmakki E, Aboshouk T, Ageely H, et al. Efficacy of immunohistochemical staining in detecting *Helicobacter pylori* in Saudi patients with minimal and atypical infection. *European journal of histochemistry : EJH*. 2021;65(3).
11. Shatila M, Thomas AS. Current and future perspectives in the diagnosis and management of *Helicobacter pylori* infection. *Journal of Clinical Medicine*. 2022;11(17):5086.
12. Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, et al. Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World journal of gastroenterology*. 2015;21(40):11221-35.



# The Research of Medical Science Review

13. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of *Helicobacter pylori* infection between 1980 and 2022: a systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology*. 2023;8(6):553-64.
14. Sousa C, Ferreira R, Santos SB, Azevedo NF, Melo LD. Advances on diagnosis of *Helicobacter pylori* infections. *Critical Reviews in Microbiology*. 2023;49(6):671-92.
15. Ansari S, Yamaoka Y. *Helicobacter pylori* infection, its laboratory diagnosis, and antimicrobial resistance: a perspective of clinical relevance. *Clinical Microbiology Reviews*. 2022;35(3):e00258-21.
16. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of *Helicobacter pylori* infection in Japan: 2016 Revised Edition. *Helicobacter*. 2019;24(4):e12597.
17. Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, et al. Diagnostic methods for *Helicobacter pylori* infection: ideals, options, and limitations. *European Journal of Clinical Microbiology & Infectious Diseases*. 2019;38:55-66.
18. Lopes AI, Vale FF, Oleastro M. *Helicobacter pylori* infection - recent developments in diagnosis. *World Journal of Gastroenterology*. 2014;20(28):9299-313.
19. Jahanzeb A, Nagi AH. Detection of *Helicobacter pylori* Through Histochemistry & Immunofluorescent Staining in Biopsies of Patients with Chronic Gastritis. *Proceedings*. 2021;34(4):4-9.
20. Smith SB, Snow AN, Perry RL, Qasem SA. *Helicobacter pylori*: to stain or not to stain? *American Journal of Clinical Pathology*. 2012;137(5):733-8.
21. Kocsmár É, Szirtes I, Kramer Z, Szijártó A, Bene L, Buzás GM, et al. Sensitivity of *Helicobacter pylori* detection by Giemsa staining is poor in comparison with immunohistochemistry and fluorescent in situ hybridization and strongly depends on inflammatory activity. *Helicobacter*. 2017;22(4):e12387.
22. Tajalli R, Nobakht M, Mohammadi-Barzelighi H, Agah S, Rastegar-Lari A, Sadeghipour A. The immunohistochemistry and toluidine blue roles for *Helicobacter pylori* detection in patients with gastritis. *Iranian Biomedical Journal*. 2013;17(1):36.
23. Benoit A, Hoyer N, Flejou J-F, editors. Diagnosis of *Helicobacter pylori* infection on gastric biopsies: Standard stain, special stain or immunohistochemistry? *Annales de Pathologie*; 2018.

The  
Research of Medical Science Review